IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study.

In T2D patients with poor metabolic control, either insulin naïve or treated with BOT or MDI, the introduction of IDegLira produces a significant increase in the time spent in good metabolic control and a marked reduction in glycemic fluctuations.